Stay updated on DPX-Survivac Therapy in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the DPX-Survivac Therapy in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the DPX-Survivac Therapy in Recurrent Ovarian Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision history shows a new v3.3.2 revision added and v3.3.1 removed, indicating a minor page update. The study content, inclusion criteria, and results have not changed.SummaryDifference0.1%

- Check21 days agoChange DetectedPage shows a minor version update from v3.2.0 to v3.3.1 with no changes to study details or eligibility information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedThe government funding/operating status notice has been removed from the page; the rest of the study details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedThe new screenshot shows only minor UI and layout adjustments (e.g., updated header area and spacing) with no changes to the study's details, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check72 days agoChange DetectedAdded a prominent government-operating status notice and new version tag (v3.2.0), while removing the old v3.1.0 revision. The page now informs users about potential delays and where to check status.SummaryDifference5%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new version is available.SummaryDifference0.1%

Stay in the know with updates to DPX-Survivac Therapy in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DPX-Survivac Therapy in Recurrent Ovarian Cancer Clinical Trial page.